<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-18087" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Bacitracin Topical</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Nguyen</surname>
            <given-names>Rosalee</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Khanna</surname>
            <given-names>Niloufar R.</given-names>
          </name>
          <aff>California Northstate University</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Safadi</surname>
            <given-names>Anthony O.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Patel</surname>
            <given-names>Preeti</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Sun</surname>
            <given-names>Yan</given-names>
          </name>
          <aff>Coney Island Hospital</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Rosalee Nguyen declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Niloufar Khanna declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Anthony Safadi declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Preeti Patel declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Yan Sun declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>8</day>
          <month>6</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-18087.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">This educational initiative on topical bacitracin offers healthcare practitioners essential insights and resources for effectively utilizing this antibiotic in treating minor skin injuries such as cuts, scrapes, and burns. Bacitracin is a staple in professional settings and home first aid kits, available as a single-agent ointment and in a triple-therapy combination with neomycin and polymyxin B. The program outlines indications, mechanisms of action, safe administration practices, adverse effects, and contraindications, emphasizing proper patient education on the application and duration of treatment to optimize outcomes. Key elements of this initiative include the emphasis on monitoring patients for signs of allergic reactions and educating healthcare providers on making informed decisions to minimize adverse effects. This educational activity seeks to enhance healthcare providers' capabilities in managing infections effectively treated with topical bacitracin, ultimately aiming to improve patient outcomes.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the indications for&#x000a0;topical bacitracin.</p></list-item><list-item><p>Evaluate&#x000a0;the antimicrobial mechanism of action of bacitracin.</p></list-item><list-item><p>Assess the potential adverse drug reactions of&#x000a0;topically-applied bacitracin.</p></list-item><list-item><p>Communicate&#x000a0;effective collaboration strategies among interprofessional team members to improve outcomes and treatment efficacy for patients who might benefit from bacitracin&#x000a0;topical therapy.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18087&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18087">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-18087.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Bacitracin, a topical antibiotic ointment, is commonly used by medical professionals and the general public to treat minor skin injuries such as cuts, scrapes, and burns. The discovery of bacitracin dates back to 1945, stemming from the wound of a 7-year-old American girl named Margaret Tracey. The debris collected from her leg injury cultured several related cyclic polypeptides produced by a member of the <italic toggle="yes">Bacillus subtilis</italic> group, which led to the naming of the antibiotic.<xref ref-type="bibr" rid="article-18087.r1">[1]</xref></p>
        <p>
<bold>United States Food and Drug Administration (FDA)-Approved Indications</bold>
</p>
        <p>FDA approved bacitracin in 1948 to prevent and treat acute and chronic localized skin infections. Bacitracin can be administered less frequently as an intramuscular injection to treat infantile streptococcal pneumonia and empyema. Bacitracin is available as a single-agent ointment or combined with neomycin and polymyxin B&#x000a0;into a triple-therapy ointment. The latter is available over the counter at local pharmacies.<xref ref-type="bibr" rid="article-18087.r2">[2]</xref> Additionally, the FDA has approved ocular bacitracin for treating superficial infections of the cornea and conjunctiva caused by susceptible organisms.</p>
        <p>
<bold>Off-Label Uses</bold>
</p>
        <p>The American Academy of Ophthalmology recommends using bacitracin for Pediculosis palpebrarum caused by <italic toggle="yes">Phthirus pubis</italic>. Forceps can remove adult lice and nits from the eyelids and eyelashes. If nits are firmly attached, the affected lashes may need to be epilated. A mild ophthalmic ointment such as bacitracin or erythromycin should be applied&#x000a0;2 to&#x000a0;3 times daily over&#x000a0;10 days to remove adult lice and nits completely.<xref ref-type="bibr" rid="article-18087.r3">[3]</xref> In a randomized controlled trial, researchers evaluated the effectiveness of various topical agents against <italic toggle="yes">Propionibacterium acnes</italic>. The results indicated that a triple antibiotic ointment containing neomycin, bacitracin, and polymyxin B effectively inhibited bacterial growth.<xref ref-type="bibr" rid="article-18087.r4">[4]</xref> The Infectious Diseases Society of America guidelines suggest oral bacitracin may be considered for treating initial <italic toggle="yes">Clostridium difficile</italic> infections. However, alternative medications are preferred due to inadequate evidence and concerns about antimicrobial resistance.<xref ref-type="bibr" rid="article-18087.r5">[5]</xref></p>
      </sec>
      <sec id="article-18087.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Bacitracin is a mixture of several closely related cyclic polypeptide antibiotics that exhibit both bacteriostatic and bactericidal properties, depending on the drug's concentration and the microorganism's susceptibility. It is effective against many gram-positive bacteria, including species of <italic toggle="yes">Staphylococcus</italic>, <italic toggle="yes">Streptococcus</italic>, <italic toggle="yes">Corynebacterium</italic>, <italic toggle="yes">Clostridium</italic>, and <italic toggle="yes">Actinomyces</italic>. Some gram-negative organisms, such as species of <italic toggle="yes">Neisseria</italic>, are also susceptible to bacitracin; however, most gram-negative organisms are resistant.<xref ref-type="bibr" rid="article-18087.r6">[6]</xref><xref ref-type="bibr" rid="article-18087.r7">[7]</xref>&#x000a0;Bacitracin is readily absorbed through denuded, burned, or granulated skin, functioning to inhibit the transfer of mucopeptides into the cell walls of various microorganisms. This action blocks bacterial cell wall synthesis and, ultimately, bacterial replication. Additionally, bacitracin inhibits proteases and other enzymes that alter bacterial cell membrane function. Specifically, it inhibits bacterial cell wall synthesis by preventing the dephosphorylation of the P-P-phospholipid carrier, which attaches the cell wall peptidoglycan precursor units to the cell membrane, resulting in bacterial cell lysis.<xref ref-type="bibr" rid="article-18087.r8">[8]</xref> The stability of bacitracin is enhanced when complexed with zinc.<xref ref-type="bibr" rid="article-18087.r9">[9]</xref></p>
        <p>
<bold>Pharmacokinetics&#x000a0;</bold>
</p>
        <p><bold>Absorption:</bold>&#x000a0;Bacitracin is poorly absorbed systemically when applied in topical, ophthalmic, and oral formulations but achieves quick and complete absorption when administered intramuscularly. However, topical bacitracin can be absorbed through burned, denuded skin or areas with granulating tissue.</p>
        <p><bold>Distribution:</bold> Bacitracin is widely distributed throughout the body, reaching all major organs. Following intramuscular injection, it is present in ascitic and pleural fluids.&#x000a0;Bacitracin exhibits minimal&#x000a0;protein binding.</p>
        <p><bold>Metabolism:</bold> Bacitracin is primarily metabolized into smaller peptides and amino acids. The primary metabolite, des-amido-bacitracin, is microbiologically inactive. Additionally, catabolic peptides are formed during the metabolism process.</p>
        <p><bold>Excretion:</bold>&#x000a0;Bacitracin is primarily excreted through the kidneys, with about 87% of an intramuscular dose&#x000a0;eliminated&#x000a0;through&#x000a0;urine within 6 hours. Hydrolytic cleavage products, including di- and tripeptides, are found in urine and bile.</p>
      </sec>
      <sec id="article-18087.s4" sec-type="Administration">
        <title>Administration</title>
        <p>
<bold>Available Dosage Forms and Strength</bold>
</p>
        <p>In the USA, bacitracin is available in topical and ophthalmic forms. The topical formulation is an ointment with a concentration of 500 units/g.</p>
        <p>
<bold>Adult Dosage</bold>
</p>
        <p><bold>Topical:&#x000a0;</bold>Bacitracin is primarily employed as a topical agent, applied directly to wounds or infected areas. Additionally, this antibiotic is available as an ophthalmic ointment formulated explicitly&#x000a0;for treating superficial infections of the conjunctiva and cornea.<xref ref-type="bibr" rid="article-18087.r10">[10]</xref></p>
        <p>Before application, the skin should be cleaned gently using mild soap and water. After cleansing, sufficient ointment must be applied to cover the affected areas. Covering the wound with a sterile dressing may aid the healing process and prevent further contamination of the wound site.</p>
        <p><bold>Ophthalmic formulation:</bold> Bacitracin ointment should be applied directly into the conjunctival sac 1 to 3 times daily. All scales and crusts must be removed in blepharitis cases, followed by a uniform ointment application over the lid margins. When applying the ointment directly to the infected eye, patients are advised to take appropriate precautions to prevent contamination.</p>
        <p>
<bold>Specific Patient Populations</bold>
</p>
        <p><bold>Hepatic impairment:</bold>&#x000a0;Edit this: Manufacturers do not provide any information regarding the dosage adjustment for bacitracin. Therefore, this medication should be used with caution.</p>
        <p><bold>Renal impairment:</bold> The parenteral formulations of bacitracin&#x000a0;can&#x000a0;cause nephrotoxicity and should be used with caution.</p>
        <p><bold>Pregnancy considerations:</bold>&#x000a0;Topical bacitracin, previously classified as FDA pregnancy risk category C, has not been extensively studied for use during pregnancy or lactation. Current evidence does not indicate an increased risk of adverse fetal development. However, due to limited data, caution is advised. Healthcare providers should carefully weigh the risks versus benefits and consider alternative treatments when feasible to ensure the safety of both mother and infant. Further research is necessary to fully understand the safety profile of topical bacitracin during pregnancy and breastfeeding.<xref ref-type="bibr" rid="article-18087.r11">[11]</xref></p>
        <p><bold>Breastfeeding considerations:</bold>&#x000a0;Topical and ophthalmic formulations of bacitracin generally exhibit minimal absorption through the skin, posing a low risk to nursing infants. Using water-soluble creams or gel products exclusively on breast tissue is recommended to reduce potential exposure from licking.<xref ref-type="bibr" rid="article-18087.r12">[12]</xref></p>
        <p>Edit this: Topical and ophthalmic formulations of bacitracin generally exhibit minimal absorption through the skin, presenting a low risk to nursing infants. To mitigate potential exposure to mineral paraffin from licking, it is recommended that water-soluble creams or gel products be used exclusively on breast tissue.<xref ref-type="bibr" rid="article-18087.r12">[12]</xref></p>
        <p><bold>Pediatric patients:</bold> Bacitracin has received FDA approval for treating blepharitis and superficial infections affecting the conjunctiva or cornea.</p>
        <p><bold>Older&#x000a0;patients:</bold>&#x000a0;See adult dosage and administration.</p>
      </sec>
      <sec id="article-18087.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>When used topically as a single agent ointment or part of a triple therapy ointment, bacitracin, and its drug formulation components may cause allergic contact dermatitis. Additionally, cases involving anaphylactic reactions to bacitracin have been reported.<xref ref-type="bibr" rid="article-18087.r13">[13]</xref></p>
        <p>Common and mild adverse effects of bacitracin include:</p>
        <list list-type="bullet">
          <list-item>
            <p>Fever</p>
          </list-item>
          <list-item>
            <p>Hives</p>
          </list-item>
          <list-item>
            <p>Itching</p>
          </list-item>
          <list-item>
            <p>Swelling of lips and face&#x000a0;<xref ref-type="bibr" rid="article-18087.r2">[2]</xref></p>
          </list-item>
          <list-item>
            <p>Difficulty breathing</p>
          </list-item>
          <list-item>
            <p>Nausea</p>
          </list-item>
          <list-item>
            <p>Vomiting&#x000a0;<xref ref-type="bibr" rid="article-18087.r14">[14]</xref></p>
          </list-item>
          <list-item>
            <p>Allergic contact dermatitis&#x000a0;<xref ref-type="bibr" rid="article-18087.r15">[15]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18087.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Topical bacitracin is contraindicated in anyone with hypersensitivity to bacitracin or its formulation components. Patients with known hypersensitivity to neomycin may also be sensitive to bacitracin. Anaphylactoid reactions have been reported.<xref ref-type="bibr" rid="article-18087.r13">[13]</xref></p>
        <p>
<bold>Warnings and Precautions</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Bacitracin application to an infection or wound caused by a viral or fungal infection may increase the risk of developing drug-resistant bacteria.</p>
          </list-item>
          <list-item>
            <p>Topical bacitracin use is recommended&#x000a0;only for minor skin injuries and should not be used over larger areas of the body.</p>
          </list-item>
          <list-item>
            <p>Before using topical bacitracin, physician consultation is recommended for serious injuries such as burns, deep wounds, puncture wounds, or animal bites.<xref ref-type="bibr" rid="article-18087.r16">[16]</xref><xref ref-type="bibr" rid="article-18087.r17">[17]</xref></p>
          </list-item>
          <list-item>
            <p>In 2020, the FDA prohibited the use of bacitracin-containing injections because of the potential&#x000a0;for nephrotoxicity.<xref ref-type="bibr" rid="article-18087.r18">[18]</xref><xref ref-type="bibr" rid="article-18087.r19">[19]</xref><xref ref-type="bibr" rid="article-18087.r20">[20]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-18087.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Secondary infections may develop; topical bacitracin should not be used for more than&#x000a0;7 days unless directed by a physician.&#x000a0;The area of application should&#x000a0;be monitored. If symptoms worsen, bacitracin use should be stopped immediately, and a clinician should be contacted&#x000a0;regarding further management.<xref ref-type="bibr" rid="article-18087.r13">[13]</xref></p>
        <p>Allergy patch testing may be necessary if an adverse reaction occurs after using bacitracin, either as a single-agent ointment or as part of a triple-therapy ointment. There have been multiple reports of anaphylactoid reactions and anaphylaxis associated with its use.<xref ref-type="bibr" rid="article-18087.r21">[21]</xref><xref ref-type="bibr" rid="article-18087.r22">[22]</xref><xref ref-type="bibr" rid="article-18087.r21">[21]</xref>&#x000a0;Furthermore, MRGPRX2, which belongs to a novel subfamily of G protein-coupled receptors (GPCRs) known as MAS-related GPCRs (MRGPRs), has been identified as a potential mediator in non-immunoglobulin E (IgE)-mediated responses. A study has shown that bacitracin can trigger MRGPRX2-dependent activation of mast cells, suggesting that non-IgE-mediated mechanisms may contribute to pseudo-allergic drug hypersensitivity reactions. This finding offers insights into the mechanism behind bacitracin-induced allergic contact dermatitis, underscoring the need for more research to thoroughly investigate and establish effective treatment options.<xref ref-type="bibr" rid="article-18087.r23">[23]</xref></p>
      </sec>
      <sec id="article-18087.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>
<bold>Signs and Symptoms of Overdose</bold>
</p>
        <p>No toxicity is reported with the topical use of bacitracin, either as a single agent or in a triple therapy ointment. However, the intramuscular route has been associated with nephrotoxicity and renal failure due to tubular and glomerular necrosis. Consequently, careful monitoring is essential for intramuscular administration of bacitracin. Renal function should be assessed before, during, and after&#x000a0;intramuscular administration to ensure safety.</p>
        <p>
<bold>Management of Overdose</bold>
</p>
        <p>Patients' daily optimal fluid intake and urinary output should be closely monitored to prevent kidney injury. Concurrent use of nephrotoxic drugs such as streptomycin, kanamycin, polymyxin E, and neomycin should be avoided.<xref ref-type="bibr" rid="article-18087.r24">[24]</xref><xref ref-type="bibr" rid="article-18087.r25">[25]</xref></p>
      </sec>
      <sec id="article-18087.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Topical bacitracin has been widely available and recognized as a safe over-the-counter topical antibiotic for the past&#x000a0;7 decades.<xref ref-type="bibr" rid="article-18087.r2">[2]</xref> However, its increased use and adverse effects led to its designation as the "contact allergen of the year" in 2003 by the American Contact Dermatitis Society.<xref ref-type="bibr" rid="article-18087.r26">[26]</xref> Between 2005 and 2006, it was identified as the sixth most common allergen in patch tests.<xref ref-type="bibr" rid="article-18087.r27">[27]</xref><xref ref-type="bibr" rid="article-18087.r28">[28]</xref>&#x000a0;All healthcare professionals should be vigilant about the potential risks of anaphylactoid reactions or anaphylaxis associated with bacitracin use. Individuals with confirmed contact dermatitis should avoid products containing bacitracin. Healthcare providers should advise patients to carefully read labels for bacitracin in ointments, creams, and other wound care products.</p>
        <p>Healthcare providers should consider bacitracin as a potential cause when encountering a patient with a possible contact allergy, persistent dermatitis, or a non-healing wound, as bacitracin allergy may mimic cellulitis or superficial wound infection. A clinical indicator distinguishing an allergic reaction from an infectious process is the presence of itching in allergic responses, as opposed to worsening pain in infections. Collaboration between dermatologists and immunologists can provide insights into distinguishing allergic dermatitis from infection. In cases of anaphylaxis caused by bacitracin, emergency medicine physicians should promptly stabilize the patient. Bacitracin should be used with caution in patients with pre-existing renal impairment or renal failure. To ensure patient safety, an interprofessional team approach involving physicians, nurses, and pharmacists is essential to monitor patients' fluid intake, urinary output, and renal function. Due to the significant risk of nephrotoxicity, pharmacists should suggest alternative medication options when available. Effective communication among clinicians (MDs, DOs, NPs, PAs), pharmacists, nurses, and specialists is crucial to optimizing patient outcomes with topical bacitracin treatment.</p>
      </sec>
      <sec id="article-18087.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=18087&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=18087">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/18087/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=18087">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-18087.s11">
        <title>References</title>
        <ref id="article-18087.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>WRONG</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>SMITH</surname>
                <given-names>RC</given-names>
              </name>
              <name>
                <surname>HUDSON</surname>
                <given-names>AL</given-names>
              </name>
              <name>
                <surname>HAIR</surname>
                <given-names>HC</given-names>
              </name>
            </person-group>
            <article-title>The treatment of pyogenic skin infections with bacitracin ointment.</article-title>
            <source>Treat Serv Bull</source>
            <year>1951</year>
            <month>Jun</month>
            <volume>6</volume>
            <issue>6</issue>
            <fpage>257</fpage>
            <page-range>257-61</page-range>
            <pub-id pub-id-type="pmid">14835814</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18087.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schalock</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Zug</surname>
                <given-names>KA</given-names>
              </name>
            </person-group>
            <article-title>Bacitracin.</article-title>
            <source>Cutis</source>
            <year>2005</year>
            <month>Aug</month>
            <volume>76</volume>
            <issue>2</issue>
            <fpage>105</fpage>
            <page-range>105-7</page-range>
            <pub-id pub-id-type="pmid">16209155</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18087.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Varu</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Rhee</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Akpek</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Amescua</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Farid</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Garcia-Ferrer</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Musch</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Mah</surname>
                <given-names>FS</given-names>
              </name>
              <name>
                <surname>Dunn</surname>
                <given-names>SP</given-names>
              </name>
              <collab>American Academy of Ophthalmology Preferred Practice Pattern Cornea and External Disease Panel</collab>
            </person-group>
            <article-title>Conjunctivitis Preferred Practice Pattern&#x000ae;.</article-title>
            <source>Ophthalmology</source>
            <year>2019</year>
            <month>Jan</month>
            <volume>126</volume>
            <issue>1</issue>
            <fpage>P94</fpage>
            <page-range>P94-P169</page-range>
            <pub-id pub-id-type="pmid">30366797</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18087.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ma</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Cao</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Antimicrobial activity of topical agents against Propionibacterium acnes: an in vitro study of clinical isolates from a hospital in Shanghai, China.</article-title>
            <source>Front Med</source>
            <year>2016</year>
            <month>Dec</month>
            <volume>10</volume>
            <issue>4</issue>
            <fpage>517</fpage>
            <page-range>517-521</page-range>
            <pub-id pub-id-type="pmid">27896620</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18087.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>McDonald</surname>
                <given-names>LC</given-names>
              </name>
              <name>
                <surname>Gerding</surname>
                <given-names>DN</given-names>
              </name>
              <name>
                <surname>Johnson</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bakken</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Carroll</surname>
                <given-names>KC</given-names>
              </name>
              <name>
                <surname>Coffin</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Dubberke</surname>
                <given-names>ER</given-names>
              </name>
              <name>
                <surname>Garey</surname>
                <given-names>KW</given-names>
              </name>
              <name>
                <surname>Gould</surname>
                <given-names>CV</given-names>
              </name>
              <name>
                <surname>Kelly</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Loo</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Shaklee Sammons</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sandora</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Wilcox</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA).</article-title>
            <source>Clin Infect Dis</source>
            <year>2018</year>
            <month>Mar</month>
            <day>19</day>
            <volume>66</volume>
            <issue>7</issue>
            <fpage>e1</fpage>
            <page-range>e1-e48</page-range>
            <pub-id pub-id-type="pmid">29462280</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18087.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Johnson</surname>
                <given-names>BA</given-names>
              </name>
              <name>
                <surname>Anker</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Meleney</surname>
                <given-names>FL</given-names>
              </name>
            </person-group>
            <article-title>BACITRACIN: A NEW ANTIBIOTIC PRODUCED BY A MEMBER OF THE B. SUBTILIS GROUP.</article-title>
            <source>Science</source>
            <year>1945</year>
            <month>Oct</month>
            <day>12</day>
            <volume>102</volume>
            <issue>2650</issue>
            <fpage>376</fpage>
            <page-range>376-7</page-range>
            <pub-id pub-id-type="pmid">17770204</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18087.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Heal</surname>
                <given-names>CF</given-names>
              </name>
              <name>
                <surname>Banks</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Lepper</surname>
                <given-names>PD</given-names>
              </name>
              <name>
                <surname>Kontopantelis</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>van Driel</surname>
                <given-names>ML</given-names>
              </name>
            </person-group>
            <article-title>Topical antibiotics for preventing surgical site infection in wounds healing by primary intention.</article-title>
            <source>Cochrane Database Syst Rev</source>
            <year>2016</year>
            <month>Nov</month>
            <day>07</day>
            <volume>11</volume>
            <issue>11</issue>
            <fpage>CD011426</fpage>
            <pub-id pub-id-type="pmid">27819748</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18087.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stone</surname>
                <given-names>KJ</given-names>
              </name>
              <name>
                <surname>Strominger</surname>
                <given-names>JL</given-names>
              </name>
            </person-group>
            <article-title>Mechanism of action of bacitracin: complexation with metal ion and C 55 -isoprenyl pyrophosphate.</article-title>
            <source>Proc Natl Acad Sci U S A</source>
            <year>1971</year>
            <month>Dec</month>
            <volume>68</volume>
            <issue>12</issue>
            <fpage>3223</fpage>
            <page-range>3223-7</page-range>
            <pub-id pub-id-type="pmid">4332017</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18087.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ray</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Gupta</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Topical antimicrobial therapy: Current status and challenges.</article-title>
            <source>Indian J Med Microbiol</source>
            <year>2019</year>
            <season>Jul-Sep</season>
            <volume>37</volume>
            <issue>3</issue>
            <fpage>299</fpage>
            <page-range>299-308</page-range>
            <pub-id pub-id-type="pmid">32003326</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18087.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gigliotti</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Hendley</surname>
                <given-names>JO</given-names>
              </name>
              <name>
                <surname>Morgan</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Michaels</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Dickens</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lohr</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of topical antibiotic therapy in acute conjunctivitis in children.</article-title>
            <source>J Pediatr</source>
            <year>1984</year>
            <month>Apr</month>
            <volume>104</volume>
            <issue>4</issue>
            <fpage>623</fpage>
            <page-range>623-6</page-range>
            <pub-id pub-id-type="pmid">6323667</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18087.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Leachman</surname>
                <given-names>SA</given-names>
              </name>
              <name>
                <surname>Reed</surname>
                <given-names>BR</given-names>
              </name>
            </person-group>
            <article-title>The use of dermatologic drugs in pregnancy and lactation.</article-title>
            <source>Dermatol Clin</source>
            <year>2006</year>
            <month>Apr</month>
            <volume>24</volume>
            <issue>2</issue>
            <fpage>167</fpage>
            <page-range>167-97, vi</page-range>
            <pub-id pub-id-type="pmid">16677965</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18087.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murase</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Heller</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Butler</surname>
                <given-names>DC</given-names>
              </name>
            </person-group>
            <article-title>Safety of dermatologic medications in pregnancy and lactation: Part I. Pregnancy.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2014</year>
            <month>Mar</month>
            <volume>70</volume>
            <issue>3</issue>
            <fpage>401.e1</fpage>
            <page-range>401.e1-14; quiz 415</page-range>
            <pub-id pub-id-type="pmid">24528911</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18087.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cronin</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Mowad</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Anaphylactic reaction to bacitracin ointment.</article-title>
            <source>Cutis</source>
            <year>2009</year>
            <month>Mar</month>
            <volume>83</volume>
            <issue>3</issue>
            <fpage>127</fpage>
            <page-range>127-9</page-range>
            <pub-id pub-id-type="pmid">19363904</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18087.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sheth</surname>
                <given-names>VM</given-names>
              </name>
              <name>
                <surname>Weitzul</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Postoperative topical antimicrobial use.</article-title>
            <source>Dermatitis</source>
            <year>2008</year>
            <season>Jul-Aug</season>
            <volume>19</volume>
            <issue>4</issue>
            <fpage>181</fpage>
            <page-range>181-9</page-range>
            <pub-id pub-id-type="pmid">18674453</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18087.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Maury</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Gruson</surname>
                <given-names>KI</given-names>
              </name>
              <name>
                <surname>Tabeayo</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Gruson</surname>
                <given-names>LM</given-names>
              </name>
              <name>
                <surname>Merchan</surname>
                <given-names>ECR</given-names>
              </name>
            </person-group>
            <article-title>Allergic Contact Dermatitis (ACD) to Topical Products in Orthopedic Surgery: Clinical Characteristics and Treatment Strategies.</article-title>
            <source>Arch Bone Jt Surg</source>
            <year>2023</year>
            <volume>11</volume>
            <issue>10</issue>
            <fpage>604</fpage>
            <page-range>604-616</page-range>
            <pub-id pub-id-type="pmid">37873527</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18087.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jones</surname>
                <given-names>RN</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Kohut</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Biedenbach</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Bell</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Turnidge</surname>
                <given-names>JD</given-names>
              </name>
            </person-group>
            <article-title>Contemporary antimicrobial activity of triple antibiotic ointment: a multiphased study of recent clinical isolates in the United States and Australia.</article-title>
            <source>Diagn Microbiol Infect Dis</source>
            <year>2006</year>
            <month>Jan</month>
            <volume>54</volume>
            <issue>1</issue>
            <fpage>63</fpage>
            <page-range>63-71</page-range>
            <pub-id pub-id-type="pmid">16368476</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18087.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bonomo</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Van Zile</surname>
                <given-names>PS</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Shermock</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>McCormick</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Kohut</surname>
                <given-names>B</given-names>
              </name>
            </person-group>
            <article-title>Topical triple-antibiotic ointment as a novel therapeutic choice in wound management and infection prevention: a practical perspective.</article-title>
            <source>Expert Rev Anti Infect Ther</source>
            <year>2007</year>
            <month>Oct</month>
            <volume>5</volume>
            <issue>5</issue>
            <fpage>773</fpage>
            <page-range>773-82</page-range>
            <pub-id pub-id-type="pmid">17914912</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18087.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Roy</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Oleru</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Amakiri</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Stratis</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kwon</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Akhavan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Henderson</surname>
                <given-names>PW</given-names>
              </name>
            </person-group>
            <article-title>Outcomes After Implant-Based Breast Reconstruction Following the National Institution of a Ban on Bacitracin Irrigation.</article-title>
            <source>Ann Plast Surg</source>
            <year>2024</year>
            <month>Apr</month>
            <day>01</day>
            <volume>92</volume>
            <issue>4S Suppl 2</issue>
            <fpage>S191</fpage>
            <page-range>S191-S195</page-range>
            <pub-id pub-id-type="pmid">38319958</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18087.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Oleru</surname>
                <given-names>OO</given-names>
              </name>
              <name>
                <surname>Akhavan</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Seyidova</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ibelli</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Taub</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Henderson</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Did the National Ban on Bacitracin Irrigation Affect Infection Rates in Implant-Based Breast Reconstruction? An Analysis of a National Database.</article-title>
            <source>Clin Breast Cancer</source>
            <year>2023</year>
            <month>Apr</month>
            <volume>23</volume>
            <issue>3</issue>
            <fpage>e103</fpage>
            <page-range>e103-e108</page-range>
            <pub-id pub-id-type="pmid">36658063</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18087.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Song</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Jiao</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Lin</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>van der Veen</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Bacitracin enhances ceftriaxone susceptibility of the high-level ceftriaxone-resistant gonococcal FC428 clone.</article-title>
            <source>Microbiol Spectr</source>
            <year>2023</year>
            <month>Dec</month>
            <day>12</day>
            <volume>11</volume>
            <issue>6</issue>
            <fpage>e0244923</fpage>
            <pub-id pub-id-type="pmid">37982635</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18087.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Katz</surname>
                <given-names>BE</given-names>
              </name>
              <name>
                <surname>Fisher</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Bacitracin: a unique topical antibiotic sensitizer.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>1987</year>
            <month>Dec</month>
            <volume>17</volume>
            <issue>6</issue>
            <fpage>1016</fpage>
            <page-range>1016-24</page-range>
            <pub-id pub-id-type="pmid">2963037</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18087.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Saryan</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Dammin</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Bouras</surname>
                <given-names>AE</given-names>
              </name>
            </person-group>
            <article-title>Anaphylaxis to topical bacitracin zinc ointment.</article-title>
            <source>Am J Emerg Med</source>
            <year>1998</year>
            <month>Sep</month>
            <volume>16</volume>
            <issue>5</issue>
            <fpage>512</fpage>
            <page-range>512-3</page-range>
            <pub-id pub-id-type="pmid">9725969</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18087.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yang</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Limjunyawong</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Peng</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Schroeder</surname>
                <given-names>JT</given-names>
              </name>
              <name>
                <surname>Saini</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>MacGlashan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Dong</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Gao</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Biological screening of a unique drug library targeting MRGPRX2.</article-title>
            <source>Front Immunol</source>
            <year>2022</year>
            <volume>13</volume>
            <fpage>997389</fpage>
            <pub-id pub-id-type="pmid">36341461</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18087.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levin</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Kagan</surname>
                <given-names>BM</given-names>
              </name>
            </person-group>
            <article-title>Antimicrobial agents: pediatric dosage, routes of administration and preparation procedures for parenteral therapy.</article-title>
            <source>Pediatr Clin North Am</source>
            <year>1968</year>
            <month>Feb</month>
            <volume>15</volume>
            <issue>1</issue>
            <fpage>275</fpage>
            <page-range>275-90</page-range>
            <pub-id pub-id-type="pmid">4295551</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18087.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>KOCH</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>DONNELL</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Staphylococcic infections in children.</article-title>
            <source>Calif Med</source>
            <year>1957</year>
            <month>Nov</month>
            <volume>87</volume>
            <issue>5</issue>
            <fpage>313</fpage>
            <page-range>313-6</page-range>
            <pub-id pub-id-type="pmid">13472470</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18087.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sood</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>JS</given-names>
              </name>
            </person-group>
            <article-title>Bacitracin: allergen of the year.</article-title>
            <source>Am J Contact Dermat</source>
            <year>2003</year>
            <month>Mar</month>
            <volume>14</volume>
            <issue>1</issue>
            <fpage>3</fpage>
            <page-range>3-4</page-range>
            <pub-id pub-id-type="pmid">14744414</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18087.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Spring</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Pratt</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Chaplin</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Contact dermatitis to topical medicaments: a retrospective chart review from the Ottawa Hospital Patch Test Clinic.</article-title>
            <source>Dermatitis</source>
            <year>2012</year>
            <season>Sep-Oct</season>
            <volume>23</volume>
            <issue>5</issue>
            <fpage>210</fpage>
            <page-range>210-3</page-range>
            <pub-id pub-id-type="pmid">23010827</pub-id>
          </element-citation>
        </ref>
        <ref id="article-18087.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zug</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Warshaw</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Fowler</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Maibach</surname>
                <given-names>HI</given-names>
              </name>
              <name>
                <surname>Belsito</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Pratt</surname>
                <given-names>MD</given-names>
              </name>
              <name>
                <surname>Sasseville</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Storrs</surname>
                <given-names>FJ</given-names>
              </name>
              <name>
                <surname>Taylor</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Mathias</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Deleo</surname>
                <given-names>VA</given-names>
              </name>
              <name>
                <surname>Rietschel</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Marks</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>Patch-test results of the North American Contact Dermatitis Group 2005-2006.</article-title>
            <source>Dermatitis</source>
            <year>2009</year>
            <season>May-Jun</season>
            <volume>20</volume>
            <issue>3</issue>
            <fpage>149</fpage>
            <page-range>149-60</page-range>
            <pub-id pub-id-type="pmid">19470301</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
